Rahal Letterman Lanigan Racing (RLL) announced today that Patients Choice Laboratories (PCL) has been named the “Official Laboratory Partner” of the team in a multi-year deal. PCL provides advanced laboratory testing specializing in molecular and toxicology diagnostics that provide precise and specific results allowing for quick diagnoses and treatment of patients. PCL performs testing in the areas of infectious diseases, including COVID-19, pharmacogenetics, and toxicology. PCL will also be an associate sponsor of the No. 15 NTT INDYCAR SERIES entry for Graham Rahal.
“The health care industry has always been one of the most integral to our daily lives and even more so the past few years,” said Bobby Rahal, co-owner of Rahal Letterman Lanigan Racing with David Letterman and Mike Lanigan. “Companies like Patient’s Choice have provided an invaluable peace of mind and helped map the path forward for many people for a variety of illnesses. Particularly given the current need for diagnostics due to the pandemic, this company has grown exponentially due to its ability to react and perform at the highest level in a very time-sensitive manner. Health care is one of the most discussed top-of-mind things in our current times. We are very pleased to have Patients Choice as a partner.”
“As a leader in infectious diseases including COVID-19, we are excited to join a growing sport and team that in many ways is similar to our own. Precision, speed, and innovation are at the forefront of Patients Choice Laboratories, Rahal Letterman Lanigan Racing, and INDYCAR,” said Brad Moss, president of PCL.
“Joining RLL as a partner, a team that is rich in tradition, winning, and respected, is special to everyone at PCL. Providing results is what we do at PCL and RLL has a history of the same. A reflection of RLL’s qualities as a team can be seen in their professionalism and extensive partnership network. We are excited to work within the RLL ecosystem, be a part of the team, and bring our expertise in medical diagnostics to help providers and patients make better treatment decisions.”